Go Deep
Biocon Limited
Biocon Limited Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Sep 2026 | 22,899 | 109.0 | 1.79 | 0.42 | 374.90 |
| Oct 2026 | 22,628 | 107.4 | 1.78 | 0.42 | 370.70 |
| Oct 2026 | 22,304 | 103.4 | 1.68 | 0.42 | 349.40 |
Biocon Limited Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 42,918,000,000.0 | 44,843,000,000.0 | 41,730,000,000.0 | 42,625,000,000.0 |
| Net Profit | 1,411,000,000.0 | 1,259,000,000.0 | 1,438,000,000.0 | 845,000,000.0 |
| EPS | 0.9 | 0.8 | 1.1 | 0.7 |
Biocon Limited Revenue & Profit: Last 4 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Revenue | 167,799,000,000.0 | 150,522,000,000.0 | 141,958,000,000.0 | 109,341,000,000.0 |
| Net Profit | 3,856,000,000.0 | 10,133,000,000.0 | 10,225,000,000.0 | 4,627,000,000.0 |
| EPS | 2.8 | 8.5 | 8.6 | 3.9 |
Biocon Limited Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 636,506,000,000.0 | 587,973,000,000.0 | 560,707,000,000.0 | 520,428,000,000.0 | — |
| Total Liabilities | 270,291,000,000.0 | 310,848,000,000.0 | 307,959,000,000.0 | 295,540,000,000.0 | — |
| Total Equity | 340,318,000,000.0 | 216,440,000,000.0 | 197,837,000,000.0 | 178,669,000,000.0 | — |
Owes vs Owns
Biocon Limited owed ₹0.42 for every ₹1 it owned in Mar 2026, down from ₹0.57 in Mar 2023.
| Period | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.42× | 0.53× | 0.55× | 0.57× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Biocon Limited Assets & Liabilities Breakdown (₹ Cr)
What it owns — Mar 2026
Cash & short-term investments 6.4%Receivables 9.4%Inventory 9.6%Fixed assets (tangible) 23.1%Intangible assets 45.3%Long-term investments 2.3%Other assets 4.0%
How it's funded — Mar 2026
Short-term debt 6.4%Long-term debt 16.9%Payables 10.6%Other liabilities 8.5%Shareholders' equity 57.5%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 4,042.6 | 4,924.2 | 3,111.8 | 3,726.0 |
| Receivables | 5,986.8 | 5,487.9 | 6,230.6 | 3,573.2 |
| Inventory | 6,085.7 | 4,931.1 | 4,943.9 | 4,243.7 |
| Fixed assets (tangible) | 14,734.1 | 13,607.8 | 12,208.2 | 10,122.6 |
| Intangible assets | 28,809.1 | 27,057.6 | 26,659.1 | 26,662.1 |
| Long-term investments | 1,439.9 | 0.0 | 0.0 | 137.8 |
| Other assets | 2,552.4 | 2,788.7 | 2,917.1 | 3,577.4 |
| Liabilities & equity | ||||
| Short-term debt | 4,078.4 | 5,350.1 | 2,797.2 | 2,480.2 |
| Long-term debt | 10,746.3 | 12,405.4 | 12,932.4 | 15,290.5 |
| Payables | 6,772.1 | 6,548.7 | 6,272.0 | 3,842.0 |
| Other liabilities | 5,432.3 | 6,780.6 | 8,794.3 | 7,941.3 |
| Shareholders' equity | 36,621.5 | 27,712.5 | 25,274.8 | 22,488.8 |
| Net tangible assets | 5,222.7 | -5,413.6 | -6,875.4 | -8,795.2 |
Biocon Limited Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | 19,940,000,000.0 | 40,612,000,000.0 | 29,539,000,000.0 | 18,525,000,000.0 | — |
| Investing Activities | -20,821,000,000.0 | -2,341,000,000.0 | -10,045,000,000.0 | -142,818,000,000.0 | — |
| Financing Activities | -9,236,000,000.0 | -18,540,000,000.0 | -23,327,000,000.0 | 130,487,000,000.0 | — |